For these studies, we chose trametinib to inhibit the MAPK pathway, as it is approved by the Food and Drug Administration (FDA), in combination with the BRAF inhibitor dabrafenib in thyroid cancer and melanoma, and dasatinib to inhibit Src, which is FDA-approved for use in chronic myeloid leukemia (CML) [19,20]. This evidence concerns the gene BRAF and thyroid gland carcinoma.